Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine in TBI with Cognitive Impairment
NCT00171795Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2002
- Primary completion
- May 2005
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial in traumatic brain injury (TBI) comparing Rivastigmine with Placebo (2 arms). Primary endpoint: Selective Attention at 20 weeks. Started Nov 2002; status: completed.
02
Drugs
rivastigmine
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00171795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171795.